Chronic Hepatitis C Virus Infection Clinical Trial
Official title:
A Blinded, Randomized, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Multiple Doses of ABT-333 Alone and in Combination With Pegylated Interferon (pegIFN) and Ribavirin (RBV) in Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection
The purpose of this study was to assess the safety, tolerability, pharmacokinetics and antiviral activity of ABT-333 (also known as dasabuvir) in treatment-naïve, hepatitis C virus (HCV)-infected participants.
This was a Phase 2a, blinded, randomized, placebo-controlled clinical trial in hepatitis C virus (HCV)-infected adults with 2 planned sequential evaluations, Part 1 and Part 2. The study evaluated the safety, tolerability, antiviral activity, and pharmacokinetics of ABT-333 or placebo monotherapy, followed by 26 days of ABT-333 or placebo with pegylated interferon a-2a (pegIFN) and ribavirin (RBV) combination therapy. Review of safety and efficacy in Part 1 of the study showed similar response rates across ABT-333 doses so Part 2 of the study was not performed. The study also assessed emergence of resistant HCV in conjunction with kinetics of viral load decay and rebound in treatment-naïve, HCV-infected participants. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01708889 -
Pharmacokinetic Study of BMS-914143 in Participants With Normal Renal Function and Mild, Moderate, Severe and End-stage Renal Dysfunction
|
Phase 1 | |
| Active, not recruiting |
NCT00563173 -
Phase I/IIa Dose Ranging CHRONVAC-C® Study in Chronic HCV Patients
|
Phase 1/Phase 2 | |
| Withdrawn |
NCT01813266 -
Prospective Cohort Study: To Provide Evidence & Guidance in Hepatitis C Virus Screening, Comparing the New Birth Cohort Recommendations From the CDC, Versus Classical Traditional Strategies With Established Risk Factors
|
||
| Completed |
NCT01121731 -
A Phase I/II Clinical Trial With Interferon Alfa 5 in Treatment-Experienced Patients With Genotype-1 Chronic Hepatitis C
|
Phase 1/Phase 2 | |
| Completed |
NCT04391985 -
Sofosbuvir/Ombitasvir/Paritaprevir/ Ritonavir and Ribavirin for Hepatitis C Virus Genotype 4 Patients
|
Phase 1/Phase 2 | |
| Completed |
NCT04387539 -
ٍٍSofosbuvir/Simeprevir/Daclatasvir/Ribavirin and HCV Genotype 4-infected Egyptian Experienced Participants
|
Phase 1/Phase 2 | |
| Completed |
NCT00770198 -
sgp130 in Chronic Human Liver Disease
|
N/A | |
| Completed |
NCT04382937 -
Ropeginterferon Alfa-2b (P1101) Phase 3 Study in Interferon Treatment-Naive Subjects With HCV Genotype 2 Infection
|
Phase 3 | |
| Completed |
NCT00606528 -
FGL2/Fibroleukin and Hepatitis C Virus Infection: A Predictor of Response to Antiviral Therapy
|
N/A | |
| Recruiting |
NCT00294489 -
Methacetin Breath Test in HCV Patients With Normal and Near-Normal ALT
|
Phase 3 | |
| Withdrawn |
NCT00255359 -
Safety, Tolerability and Efficacy of XTL 2125 in HCV-Infected Patients Who Are Interferon-Alpha Non-Responders or Relapsers
|
Phase 1 | |
| Completed |
NCT00570336 -
Study of CTS-1027 in Hepatitis C Patients
|
Phase 2 | |
| Completed |
NCT02292719 -
A Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir With Sofosbuvir With or Without Ribavirin in Adults With Chronic Hepatitis C Virus Infection
|
Phase 2 | |
| Terminated |
NCT01080222 -
A Safety and Efficacy Study of the Combination of VX-222 and Telaprevir in Treatment-Naïve Subjects With Genotype 1 Chronic Hepatitis C Virus Infection
|
Phase 2 | |
| Completed |
NCT04385407 -
Sofosbuvir With Ribavirin or Simeprevir With HCV GT4 Egyptian Patients
|
Phase 2 | |
| Completed |
NCT04387526 -
Sofosbuvir Plus Daclatasvir With or Without Ribavirin and Chronic HCV Genotype (GT) 4
|
Phase 2/Phase 3 | |
| Completed |
NCT00215865 -
PEG-Interferon a-2b + Ribavirin for Treatment of Patients With Chronic Hepatitis C Who Have Previously Failed to Achieve a Sustained Virologic Response Following Interferon Alfa or Interferon a-2b + Ribavirin Therapy
|
Phase 3 |